Company news

EXACT Therapeutics AS news in 2026

EXACT Therapeutics AS's news releases, calls and decks from 2026, newest first.

View company

EXACT Therapeutics publishes shareholder information regarding the delisting

September 4, 2026

EXACT Therapeutics AS - Issuance of share options

August 31, 2026

EXACT Therapeutics AS: Oslo Stock Exchange approves application to delist EXACT Therapeutics’ shares

July 2, 2026

EXACT Therapeutics AS - Removal from trading

June 30, 2026

EXACT Therapeutics: Announces webcast regarding strategic intent to delist the company's shares from listing on Euronext Growth, Oslo

June 1, 2026

EXACT Therapeutics: Strategic intent to delist the company's shares from listing on Euronext Growth, Oslo

May 29, 2026

EXACT Therapeutics AS: Share capital increase registered

March 26, 2026

Notice of Extraordinary General Meeting for EXACT Therapeutics March 13, 2026

March 13, 2026

First patient dosed in Europe in Phase 2 trial in patients with locally advanced pancreatic cancer

March 3, 2026

EXACT Therapeutics AS: Notice of extraordinary general meeting

February 27, 2026

EXACT Therapeutics AS: Warrants exercise

February 27, 2026

EXACT Therapeutics: Investor presentation for the global investor call regarding the ongoing warrants exercise program

February 11, 2026

EXACT Therapeutics: Global investor call regarding the ongoing warrants exercise program

February 6, 2026

EXACT Therapeutics: Exercise of Warrants by GE Medical Holding AB

February 5, 2026

EXACT Therapeutics: Positive initial safety read-out from the Phase 2 ENACT trial in pancreatic cancer, triggering option to exercise warrants

January 27, 2026

Positive initial safety read-out from the Phase 2 ENACT trial in pancreatic cancer, triggering option to exercise warrants

January 27, 2026

Decks in 2026